Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.

First Quarter Ended March 31, 2024, Financial Highlights (Compared to the First Quarter of 2023) Revenue increased by 8% to $6.9 million from $6.4 million.Gross Profit increased by 139% to $3.8 million from $1.6 million.Gross Profit margin increased by 123% to 55% from 25%.Operating Income improved by $1.8 million to $0.7 million compared to an Operating Loss of ($1.1) million.Operating Margin improved by 27.2 percentage points to 10.5% from negative margin of (16.7%).Net Income improved by $2.3 million to $0.8 million compared to Net Loss of ($1.5) million.EPS improved by $0.36 to positive $0.04 compared to Negative EPS of ($0.32).Non-GAAP ...

Total Revenue Increased 61% Year-over-Year; Mobile Revenue Grew nearly 200% Year-over-Year, Reaching a Record 61% of Total Revenue PORTLAND, Ore., May 14, 2024 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative video and display processing solutions, today announced financial results for the first quarter ended March 31, 2024.

AEye, Inc. (Nasdaq: LIDR), a global leader in adaptive, high performance lidar solutions, today announced its results for the first quarter ended March 31, 2024.